First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience. Mediterranean Journal of Hematology and Infectious Diseases, [S. l.], v. 18, n. 1, p. e2026066, 2026. DOI: 10.4084/MJHID.2026.066. Disponível em: https://www.mjhid.org/mjhid/article/view/6449. Acesso em: 2 sep. 2026.